Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
national top stories
new york blog main
new york top stories
7
×
boston blog main
boston top stories
san francisco blog main
san francisco top stories
san diego blog main
san diego top stories
biotech
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
drugs
fda
national
amgen
cancer
cholesterol
deals
eli lilly
gene therapy
indiana blog main
indiana top stories
ipo
jefferies
ldl
new york
What
big
7
×
week
ago
ceo
companies
drug
make
medical
medicine
medicines
meeting
new
startup
year
abuzz
aces
admits
aiming
amarin
ambys
american
announced
approval
arguments
ash
bio
biotech
biotechs
blood
bosley's
bosley’s
bridge
bucks
cas
cholesterol
class
classes
clinical
combinator
commercialized
Language
unset
Current search:
big
×
" new york top stories "
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Deeper Dive: Amarin Fish-Oil Study Gives Eager Doctors More to Ponder
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?